

SOUTH SUDAN Support for Meningitis A Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: South Sudan								
2. Grant number: 17-SDS-16a-X / 17-SDS-17a-Y								
3. Date of Decision Letter: 13 June 2017								
4. Date of the Partnership Framework Agreement: 10 July 2013								
5. Programme title: New Vaccine Support (NVS), Meningitis A Preventive Campaign								
6. Vaccine type: Meningitis A								
7. Requested product presentation and formulation of vaccine: Meningococcal type A, 10 dose(s) per vial, LYOPHILISED								
8. Programme duration¹: 2017								
9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)								
	2017	Total ²						
Programme Budget (US\$)	US\$1,554,000	US\$1,554,000						
10. Vaccine introduction grant (in US\$): . Not applicable								
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ³								
Type of supplies to be purchased with Gavi funds in each year	2017							
Number of Meningitis A vaccines doses	2,357,000							
Annual Amounts (US\$)	US\$1,554,000							
<p>For information and reference, the related Injection Safety Devices to be purchased under Gavi funds for 2017 shall be included in a separate Decision Letter (Grant Number 17-SDS-32a-X):</p> <table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">New Vaccine Support (NVS), Meningococcal type A, 10 dose(s) per vial, LYOPHILISED,Campaign</th> <th style="text-align: center;">2017</th> </tr> </thead> <tbody> <tr> <td>Number of AD syringes</td> <td style="text-align: center;">3,559,000</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td style="text-align: center;">395,100</td> </tr> </tbody> </table>			New Vaccine Support (NVS), Meningococcal type A, 10 dose(s) per vial, LYOPHILISED,Campaign	2017	Number of AD syringes	3,559,000	Number of re-constitution syringes	395,100
New Vaccine Support (NVS), Meningococcal type A, 10 dose(s) per vial, LYOPHILISED,Campaign	2017							
Number of AD syringes	3,559,000							
Number of re-constitution syringes	395,100							

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

	Number of safety boxes	43,500
	Annual Amounts for injection safety devices for Vaccine (US\$)	195,000
12. Procurement agency: UNICEF		
13. Self-procurement: Not applicable		
14. Co-financing obligations: Not applicable		
15. Operational support for campaigns: The support for operational costs for campaign will be disbursed in cash through WHO/UNICEF. MoH in collaboration with WHO/UNICEF shall ensure utilisation of GAVI funds according to the approved operational plan and budget of the campaign.		
		2017
	Grant amount (US\$)	US\$1,246,247
16. Additional reporting requirements: Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts: Not applicable		
Reports and other information	Due dates	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat	
Submit SIA technical report	3 months after the campaign	
Submit an independent campaign coverage survey report	3 months after the campaign	
Submit a financial expenditure report	3 months after the campaign	
Submit a close out plan using Gavi template	3 months after the campaign	
17. Financial clarifications: Not applicable		
18. Other conditions: Any change to the initial planned date of the campaign should immediately be notified to Gavi.		

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

13 June 2017